620 related articles for article (PubMed ID: 14534679)
1. Cisplatin and platinum drugs at the molecular level. (Review).
Boulikas T; Vougiouka M
Oncol Rep; 2003; 10(6):1663-82. PubMed ID: 14534679
[TBL] [Abstract][Full Text] [Related]
2. Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance.
Kelland LR; Sharp SY; O'Neill CF; Raynaud FI; Beale PJ; Judson IR
J Inorg Biochem; 1999 Oct; 77(1-2):111-5. PubMed ID: 10626362
[TBL] [Abstract][Full Text] [Related]
3. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
O'Neill CF; Koberle B; Masters JR; Kelland LR
Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
[TBL] [Abstract][Full Text] [Related]
4. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research.
Ali BH; Al Moundhri MS
Food Chem Toxicol; 2006 Aug; 44(8):1173-83. PubMed ID: 16530908
[TBL] [Abstract][Full Text] [Related]
5. Cellular processing of platinum anticancer drugs.
Wang D; Lippard SJ
Nat Rev Drug Discov; 2005 Apr; 4(4):307-20. PubMed ID: 15789122
[TBL] [Abstract][Full Text] [Related]
6. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.
Reardon JT; Vaisman A; Chaney SG; Sancar A
Cancer Res; 1999 Aug; 59(16):3968-71. PubMed ID: 10463593
[TBL] [Abstract][Full Text] [Related]
7. Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: Possible mechanisms of cell resistance.
Brenes O; Arce F; Gätjens-Boniche O; Díaz C
Biomed Pharmacother; 2007 Jul; 61(6):347-55. PubMed ID: 17399942
[TBL] [Abstract][Full Text] [Related]
8. Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes.
Ahmad S
Chem Biodivers; 2010 Mar; 7(3):543-66. PubMed ID: 20232326
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin: mode of cytotoxic action and molecular basis of resistance.
Siddik ZH
Oncogene; 2003 Oct; 22(47):7265-79. PubMed ID: 14576837
[TBL] [Abstract][Full Text] [Related]
10. Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses.
Konstantakou EG; Voutsinas GE; Karkoulis PK; Aravantinos G; Margaritis LH; Stravopodis DJ
Int J Oncol; 2009 Aug; 35(2):401-16. PubMed ID: 19578756
[TBL] [Abstract][Full Text] [Related]
11. [Platinum salts: cytotoxic mechanisms of action, mechanisms of resistance of cancer cells, interactions with ionizing radiation, specificity of carboplatin].
Rixe O
Bull Cancer; 2000 Aug; 87 Spec No():7-15. PubMed ID: 11082717
[TBL] [Abstract][Full Text] [Related]
12. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
Brabec V; Nováková O
Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
[TBL] [Abstract][Full Text] [Related]
13. Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells.
Martelli L; Di Mario F; Ragazzi E; Apostoli P; Leone R; Perego P; Fumagalli G
Biochem Pharmacol; 2006 Sep; 72(6):693-700. PubMed ID: 16844093
[TBL] [Abstract][Full Text] [Related]
14. Platinum resistance: laboratory findings and clinical implications.
Muggia FM; Los G
Stem Cells; 1993 May; 11(3):182-93. PubMed ID: 8318904
[TBL] [Abstract][Full Text] [Related]
15. Insights into mechanisms of cisplatin resistance and potential for its clinical reversal.
Gosland M; Lum B; Schimmelpfennig J; Baker J; Doukas M
Pharmacotherapy; 1996; 16(1):16-39. PubMed ID: 8700790
[TBL] [Abstract][Full Text] [Related]
16. Analysis of cytotoxicities of platinum compounds.
Goodisman J; Hagrman D; Tacka KA; Souid AK
Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101
[TBL] [Abstract][Full Text] [Related]
17. The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway.
Wu YJ; Muldoon LL; Neuwelt EA
J Pharmacol Exp Ther; 2005 Feb; 312(2):424-31. PubMed ID: 15496615
[TBL] [Abstract][Full Text] [Related]
18. The novel platinum(IV) complex LA-12 induces p53 and p53/47 responses that differ from the related drug, cisplatin.
Hrstka R; Powell DJ; Kvardova V; Roubalova E; Bourougaa K; Candeias MM; Sova P; Zak F; Fåhraeus R; Vojtĕsek B
Anticancer Drugs; 2008 Apr; 19(4):369-79. PubMed ID: 18454047
[TBL] [Abstract][Full Text] [Related]
19. The altered apoptotic pathways in cisplatin and etoposide-resistant melanoma cells are drug specific.
Kissel CK; Schadendorf D; Röckmann H
Melanoma Res; 2006 Dec; 16(6):527-35. PubMed ID: 17119454
[TBL] [Abstract][Full Text] [Related]
20. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]